IOSP INNOSPEC INC.
Chemicals & Allied Products · Nasdaq · SEC CIK 1054905 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.7%
TTM net income YoY2,749.1%
TTM EPS YoY14,250.0%
Revenue 3-yr CAGR-1.6%
Net income 3-yr CAGR3.4%
Margins
Gross margin27.7%
Operating margin8.8%
Net margin7.5%
FCF margin2.5%
EBITDA margin10.9%
Returns
ROE10.5%
ROA7.7%
ROIC (approx.)12.4%
Asset turnover1.03x
Leverage & solvency
Liabilities / assets25.7%
Debt / equity0.00x
Current ratio2.95x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio2.0%
Payout ratio—
Capex / revenue3.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.78B | $1.85B | $1.95B | $1.96B | $1.48B |
| Cost of revenue | $1.29B | $1.30B | $1.36B | $1.38B | $1.05B |
| Gross profit | $492.40M | $542.90M | $591.10M | $586.70M | $434.90M |
| R&D expense | $51.00M | $56.50M | $49.00M | $38.70M | $37.40M |
| SG&A expense | $285.10M | $305.30M | $380.50M | $360.70M | $267.20M |
| Operating income | $129.50M | $177.90M | $161.60M | $187.30M | $132.10M |
| Interest expense | $0 | $0 | $0 | $0 | $0 |
| Pretax income | $138.10M | $41.20M | $174.40M | $184.60M | $134.40M |
| Income tax | $21.50M | $5.60M | $35.30M | $51.60M | $41.30M |
| Net income | $116.60M | $33.20M | $139.00M | $133.00M | $93.00M |
| EBITDA | $173.10M | $221.40M | $200.90M | $227.40M | $174.80M |
| EPS (basic) | 4.69 | 1.43 | 5.60 | 5.37 | 3.78 |
| EPS (diluted) | 4.67 | 1.42 | 5.56 | 5.32 | 3.75 |
| Dividends declared per share | 1.71 | 1.55 | 1.41 | 1.28 | 1.16 |
| Weighted avg. shares (diluted) | 24.99M | 25.12M | 25.02M | 24.98M | 24.85M |
| Balance sheet | |||||
| Cash & equivalents | $292.50M | $289.20M | $203.70M | $147.10M | $141.80M |
| Receivables | $342.30M | $341.70M | $359.80M | $334.60M | $284.50M |
| Inventory | $329.30M | $301.00M | $300.10M | $373.10M | $277.60M |
| Current assets | $1.00B | $956.60M | $885.70M | $872.60M | $728.10M |
| PP&E, net | $286.10M | $269.70M | $268.30M | $220.90M | $214.40M |
| Goodwill | $399.00M | $382.50M | $399.30M | $358.80M | $364.30M |
| Intangibles | $67.70M | $65.40M | $57.30M | $45.00M | $57.50M |
| Total assets | $1.83B | $1.73B | $1.71B | $1.60B | $1.57B |
| Current liabilities | $360.10M | $371.40M | $371.50M | $405.80M | $336.60M |
| Total liabilities | $499.50M | $518.60M | $557.80M | $563.30M | $537.90M |
| Shareholders' equity | $1.33B | $1.21B | $1.15B | $1.04B | $1.03B |
| Cash flow statement | |||||
| Operating cash flow | $138.30M | $184.50M | $207.30M | $81.70M | $93.20M |
| Capital expenditure | $50.30M | $41.40M | $62.10M | $39.60M | $39.10M |
| Free cash flow | $88.00M | $143.10M | $145.20M | $42.10M | $54.10M |
| Investing cash flow | -$75.10M | -$62.00M | -$111.80M | -$42.10M | -$36.20M |
| Financing cash flow | -$63.90M | -$35.30M | -$39.00M | -$33.70M | -$20.00M |
| Depreciation & amortization | $43.60M | $43.50M | $39.30M | $40.10M | $42.70M |
| Stock-based compensation | $8.10M | $8.50M | $8.00M | $6.70M | $4.40M |
| Dividends paid | $42.40M | $38.80M | $35.10M | $31.70M | $28.80M |
| Share buybacks | $23.90M | $700,000 | $1.10M | $5.90M | $800,000 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.